{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:31:32Z","timestamp":1792697492634,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Identification of risk factors for early mortality (EM) in multiple myeloma (MM) patients may contribute to different therapeutic approaches in patients at risk for EM. This population-based study aimed to assess trends in EM and risk factors for EM among MM patients diagnosed in the Netherlands. All MM patients, newly diagnosed between 1989 and 2018, were identified in the Netherlands Cancer Registry. Patients were categorized into three calendar periods (1989\u20131998, 1999\u20132008, 2009\u20132018) and into five age groups (\u226465, 66\u201370, 71\u201375, 76\u201380, &gt;80 years). EM was defined as death by any cause \u2264180 days post-diagnosis. We included 28,328 MM patients (median age 70 years; 55% males). EM decreased from 22% for patients diagnosed in 1989\u20131998 to 13% for patients diagnosed in 2009\u20132018 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) and this decrease was observed among all age groups. Exact causes of death could not be elucidated. Besides patient\u2019s age, we found that features related to a more aggressive disease presentation, and patient characteristics reflecting patients\u2019 physical condition were predictive of EM. In summary, EM decreased from 1999 onwards. Nevertheless, EM remains high, especially for patients aged &gt;70 years. Therefore, novel strategies should be explored to improve the outcome of patients at risk for EM.<\/jats:p>","DOI":"10.1038\/s41408-021-00571-8","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T09:02:37Z","timestamp":1636621357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-4810","authenticated-orcid":false,"given":"Mirian","family":"Brink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaz","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0808-2237","authenticated-orcid":false,"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-8379","authenticated-orcid":false,"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"Broijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4767-6716","authenticated-orcid":false,"given":"Avinash G.","family":"Dinmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"van der Spek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-3547","authenticated-orcid":false,"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula F.","family":"Ypma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"de Waal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardus F. M. Ward","family":"Posthuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"571_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.critrevonc.2018.07.003","volume":"130","author":"S Bringhen","year":"2018","unstructured":"Bringhen S, Offidani M, Palmieri S, Pisani F, Rizzi R, Spada S, et al. Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: a pooled analysis. Crit Rev Oncol Hematol. 2018;130:27\u201335.","journal-title":"Crit Rev Oncol Hematol"},{"key":"571_CR2","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122\u20138.","journal-title":"Leukemia"},{"key":"571_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2645-y","volume":"16","author":"SH Jung","year":"2016","unstructured":"Jung SH, Cho MS, Kim HK, Kim SJ, Kim K, Cheong JW, et al. Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. BMC Cancer. 2016;16:613.","journal-title":"BMC Cancer"},{"key":"571_CR4","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.1002\/ajh.25320","volume":"94","author":"M Galli","year":"2019","unstructured":"Galli M, Paris L, Pavoni C, Delaini F, Rambaldi A. Effect of novel agents on the risk of early death of newly diagnosed symptomatic multiple myeloma patients: a single centre retrospective analysis. Am J Hematol. 2019;94:E11\u20133.","journal-title":"Am J Hematol"},{"key":"571_CR5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/ajh.24796","volume":"92","author":"H Terebelo","year":"2017","unstructured":"Terebelo H, Srinivasan S, Narang M, Abonour R, Gasparetto C, Toomey K, et al. Recognition of early mortality in multiple myeloma by a prediction matrix. Am J Hematol. 2017;92:915\u201323.","journal-title":"Am J Hematol"},{"key":"571_CR6","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1016\/j.clml.2020.12.023","volume":"21","author":"V Kumar","year":"2021","unstructured":"Kumar V, Ailawadhi M, Dutta N, Abdulazez M, Aggarwal CS, et al. Trends in early mortality from multiple myeloma: a population-based analysis. Clin Lymphoma Myeloma Leuk. 2021;21:e449\u201355.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"571_CR7","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219\u201326.","journal-title":"J Clin Oncol"},{"key":"571_CR8","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/10245332.2015.1101969","volume":"21","author":"YK Chen","year":"2016","unstructured":"Chen YK, Han SM, Yang Y, Lin TH, Tzeng HE, Chang KH, et al. Early mortality in multiple myeloma: experiences from a single institution. Hematology. 2016;21:392\u20138.","journal-title":"Hematology"},{"key":"571_CR9","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.3390\/cancers12113106","volume":"12","author":"F Bonello","year":"2020","unstructured":"Bonello F, Boccadoro M, Larocca A. Diagnostic and therapeutic challenges in the management of intermediate and frail elderly multiple myeloma patients. Cancers. 2020;12:3106.","journal-title":"Cancers"},{"key":"571_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjh.15261","volume":"182","author":"EK O\u2019Donnel","year":"2018","unstructured":"O\u2019Donnel EK, Laubach JP, Yee AJ, Chen T, Huff CA, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant - ineligible multiple myeloma. Br J Haematol. 2018;182:222\u201330.","journal-title":"Br J Haematol"},{"key":"571_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, et al. Lenalidomide plus high-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29\u201337.","journal-title":"Lancet Oncol"},{"key":"571_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107\u201313.","journal-title":"Haematologica"},{"key":"571_CR13","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","volume":"20","author":"MT Drayson","year":"2019","unstructured":"Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2019;20:1760\u201372.","journal-title":"Lancet Oncol"},{"key":"571_CR14","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3324\/haematol.2012.075051","volume":"98","author":"S Bringhen","year":"2013","unstructured":"Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98:980\u20137.","journal-title":"Haematologica"},{"key":"571_CR15","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00571-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00571-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00571-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:24:22Z","timestamp":1669919062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00571-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["571"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00571-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]},"assertion":[{"value":"24 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}